ethyl (1S)-2-oxocyclohexane-1-carboxylate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl (1S)-2-oxocyclohexane-1-carboxylate
• 化学式: C₉H₁₄O₃
• 分子量: 170.208
• InChiKey: FGSGHBPKHFDJOP-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苹果酯 、 ethyl (1S)-2-oxocyclohexane-1-carboxylate 在 sodium ethanolate 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 14.0h， 生成
  参考文献：
  名称：

  Synthesis, activity and mechanism for double-ring conjugated enones

  摘要：

  DOI：

  10.1016/j.bmcl.2021.128315

文献信息

• [EN] CARBAZOLE AND CARBOLINE KINASE INHIBITORS<br/>[FR] CARBAZOLE ET INHIBITEURS DE LA CARBOLINE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010080474A1

  公开（公告）日：2010-07-15

  The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

  本发明提供了式（I）的化合物及其药用可接受的盐。式（I）的化合物抑制Jak2的酪氨酸激酶活性，因此使它们在作为抗增殖剂治疗癌症和其他疾病方面有用。
• CARBAZOLE AND CARBOLINE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2370407A1

  公开（公告）日：2011-10-05
• METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO
  申请人：Owen David

  公开号：US20140301947A1

  公开（公告）日：2014-10-09

  A method for aiding in selecting or adjusting a dose of TSPO imaging or therapeutic agent for use with a subject, the method comprising the step of determining the subject's genotype for TSPO rs6971. A TSPO imaging or therapeutic agent for use in TSPO imaging or therapy in a subject, wherein the subject is a subject whose genotype at TSPO polymorphism position rs6971 is determined. The subject's genotype for TSPO may be taken into account when assessing the results of the TSPO imaging, for example normalising the subject's determined measure of binding of the TSPO agent to take account of the subject's determined genotype. The subject's genotype for TSPO may be taken into account when choosing the TSPO agent and/or the dose of TSPO agent. The subject may be a subject who has been determined to have genotype CC or CT at TSPO polymorphism position rs6971, for example when using a TSPO agent that binds with higher affinity to Aia147TSPO than to Thr147TSPO.